Lisa Lacasse: Fourth Chief Patient Officer Summit panel discusses biomarker testing policy

Lisa Lacasse shared a post on LinkedIn:

“I had the pleasure of joining Mary Wachter, RN, Executive Director, State and Local Government Affairs Genentech and Rep. Meghan Kilcoyne, champion and House Sponsor of the MA Biomarkers Bill, today in Boston at the Fourth Chief Patient Officer Summit.

During the panel we discussed biomarker testing policy and I shared how American Cancer Society Cancer Action Network (ACS CAN) partners with stakeholders across industry, other patient advocacy groups and with government officials on both sides of the aisle to increase patient access to this critical personalized medicine.

We’ve successfully advocated for enactment strong biomarker testing coverage laws in 20 states and are working towards enacting similar laws in all states.

However, our work doesn’t end with the passage of these laws. We are also collaborating with our partners to monitor and support the implementation of these policies to ensure that patients are benefiting from them.

If you’d like to learn more, visit here.”

Source: Lisa Lacasse/LinkedIn

Lisa Lacasse, President of the American Cancer Society Cancer Action Network (ACS CAN), has an impactful leadership in healthcare advocacy. Leading ACS CAN’s nationwide public policy advocacy agenda with her oversight of a dedicated team in Washington, D.C., she ensures effective advocacy efforts at the highest levels.

Beyond her role at ACS CAN, Lacasse’s commitment to public health extends to serving on the board for the Campaign for Tobacco-Free Kids. Her approach and dedication continue to drive positive change in the fight against cancer and tobacco-related diseases.